October 6th, 2025 | 07:20 CEST
Biotech: Small innovations, big impact with Teva Pharmaceutical, BioNxt and Lonza Group
Anyone investing in biotech hopes to have the next big breakthrough in their portfolio: active ingredients that revolutionize everything, technologies that make a difference. In reality, however, biotechnology is characterized by many small but meaningful improvements. From an investor's perspective, it is also worth keeping an eye on these incremental advances. The reason: while the search for new, groundbreaking active ingredients is often a hit-or-miss business, small advances make it possible to generate consistent returns with relatively low capital expenditure. We present three promising business models that demonstrate the value-creation potential of incremental innovation.
time to read: 3 minutes
|
Author:
Nico Popp
ISIN:
TEVA PHARMACEUT. SP.ADR | US8816242098 , Bionxt Solutions Inc. | CA0909741062 , LONZA GROUP AG NA SF 1 | CH0013841017
Table of contents:

"[...] Defence will continue to develop its Antibody Drug Conjugates "ADC" and its radiopharmaceuticals programs, which are currently two of the hottest products in demand in the pharma industries where significant consolidations and take-overs occurred. [...]" Sébastien Plouffe, CEO, Founder and Director, Defence Therapeutics Inc.
Author
Nico Popp
At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.
Tag cloud
Shares cloud
Innovative dosage forms for greater adherence to therapy and new areas of application
Innovative dosage forms demonstrate that it is not always about the next blockbuster drug. Keywords such as extended release, long-acting injectables, and sublingual drug films describe innovations that get more out of existing active ingredients. This is the case, for example, when substances are released gradually rather than immediately, or when a single monthly dose is sufficient, so patients no longer have to think about their medication every day. Even replacing an injection with an active ingredient film that dissolves on the tongue can often improve therapeutic success. Experts view innovative dosage forms as a way to improve treatment adherence, expand target groups, and unlock additional areas of application. One example is the oral administration of active ingredients for obesity in children: While many children shy away from regular injections, there are no such barriers with tablets or dissolvable films. Similarly, patients who have difficulty swallowing can benefit from alternative dosage forms.
Teva Pharmaceutical makes life easier for patients
The generic drug specialist Teva Pharmaceutical has been focusing on higher-margin specialty generics for some time now, specifically addressing issues of treatment adherence and convenience. This strategy enables the Company to achieve higher margins while delivering tangible medical benefits. One example is Austedo, a tablet used to treat movement disorders and Huntington's disease. Previously, patients had to take tablets several times a day. Austedo, by contrast, is taken just once daily, simplifying treatment and significantly increasing its success. Teva has also launched the antipsychotic drug UZEDY based on the same principle. Instead of daily tablets, which are challenging to take, especially for people with psychosis, UZEDY is administered by injection every one to two months – a real game changer for many people with schizophrenia.
BioNxt: Advances in obesity and MS
The German-Canadian biotech company BioNxt is also following in the footsteps of Teva Pharmaceutical. BioNxt researchers focus on innovative dosage forms, and in the past have concentrated in particular on active ingredient patches for the continuous delivery of the Parkinson's drug rotigotine. For some time now, the Company has also seen great potential in sublingual drug films. These can transport, among other things, the multiple sclerosis drug cladribine and semaglutide, the active ingredient in weight loss injections. In both cases, administration via a dissolvable film offers major advantages. This applies, for example, to MS patients with swallowing difficulties or obese patients who shy away from weekly injections.
The current developments surrounding cladribine in connection with the autoimmune disease myasthenia gravis also illustrate how closely BioNxt is aligning its activities with the current state of research and what potential this could bring. Merck is currently conducting a Phase 3 trial to evaluate the use of cladribine capsules in treating myasthenia gravis. If the study is successful, this will open up another potential market for BioNxt. In the case of the weight loss drug semaglutide, it currently appears that this active ingredient could also be effective against the degenerative liver disease MASH, colloquially known as "fatty liver disease." Studies show that many obese patients already exhibit early signs of MASH. If this condition is treated in a more targeted manner, BioNxt's sublingual delivery technology could benefit from an expanding therapeutic market.
Lonza impresses with innovative solutions and the entire value chain
The figures from Lonza, a company specializing in contract research and manufacturing, also show that innovative dosage forms and unique solutions in the pharmaceutical sector promise attractive growth. Lonza offers its customers the complete value chain from early drug development to commercial manufacturing and specializes in tailor-made release profiles and solutions for masking unpleasant tastes. This profile has a positive impact on sales – in the first half of the year, Lonza's sales climbed by a whopping 19%. As a comprehensive service provider in the biotech and pharmaceutical segment, Lonza is also benefiting from growing concerns about supply chain disruptions. Many clients now prefer integrated, one-stop solutions, further strengthening Lonza's competitive position.
Corporations or small caps – Who is winning the race on the stock market?
While Teva Pharmaceutical and Lonza Group are valued at tens of billions, BioNxt is considered a small cap – the Company is valued at just under CAD 100 million. In order to benefit from the trend toward innovative dosage forms and the expansion of target groups for proven active ingredients, the stock offers a good entry point for speculative investors. After a hype in the summer, the stock has now consolidated.

Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.
In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
For this reason, there is a concrete conflict of interest.
The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.
Risk notice
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.
The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.